Hyperkalemia Does Not Cause AKI—It Is a Consequence, Not a Cause
Elevated potassium levels do not cause acute kidney injury; rather, hyperkalemia is typically a consequence of AKI or occurs alongside it due to shared underlying pathophysiology. The relationship is reversed from what the question implies.
Understanding the Directional Relationship
The evidence consistently demonstrates that hyperkalemia and AKI share common etiologies but hyperkalemia does not cause kidney injury:
- AKI causes hyperkalemia through impaired renal potassium excretion when kidney function deteriorates 1
- Both conditions frequently coexist due to shared risk factors including medications (RAASi, MRAs), volume depletion, and underlying chronic conditions like CKD, heart failure, and diabetes 2, 1
- Recent data shows hyperkalemia is associated with worse outcomes in patients who already have AKI—including progression of kidney injury, need for dialysis, and death—but this represents a marker of severity rather than a causal mechanism 3
The Clinical Evidence
A 2025 study of hospitalized AKI patients found that 21% developed a composite outcome of AKI progression, dialysis, or death within 14 days, with hyperkalemia independently associated with these adverse outcomes (OR 2.41 for composite outcome, OR 1.76 for AKI progression) 3. However, this association reflects that hyperkalemia indicates more severe kidney dysfunction and metabolic derangement, not that potassium itself damages the kidneys.
The U-shaped mortality curve associated with potassium levels (nadir at 4.1-4.2 mEq/L) demonstrates that both hypo- and hyperkalemia predict poor outcomes, but through different mechanisms—primarily cardiac arrhythmias and metabolic disturbances rather than direct nephrotoxicity 1, 3.
Common Clinical Scenarios Creating Confusion
Medication-induced scenarios often create the appearance of causality:
- RAASi therapy (ACEi, ARBs, MRAs) can precipitate both hyperkalemia AND AKI simultaneously through hemodynamic effects on glomerular filtration 4, 5
- Spironolactone use increases risk of both hyperkalemia (HR 1.69) and AKI (HR 1.12) in heart failure patients, but these are parallel consequences of the drug's mechanism, not sequential events 4
- Case reports of "life-threatening hyperkalemia" with rising creatinine describe situations where volume depletion or medication effects caused AKI, which then led to potassium retention 6, 7
Critical Pitfall to Avoid
Do not attribute rising creatinine to hyperkalemia itself. When both are present, search for the true underlying cause:
- Volume depletion or shock
- Urinary obstruction
- Medication effects (RAASi, NSAIDs)
- Underlying CKD progression
- Metabolic acidosis
The hyperkalemia is a biochemical marker of the kidney's inability to excrete potassium due to the injury, not the injurious agent 1, 8.
Management Implications
Since hyperkalemia doesn't cause AKI, treatment priorities differ:
- Treat hyperkalemia urgently for cardiac protection (membrane stabilization, potassium shifting, removal) when severe 8
- Simultaneously address the underlying cause of AKI (restore perfusion, relieve obstruction, adjust medications)
- Do not assume that correcting hyperkalemia will improve kidney function—both require independent management 2, 1
- In chronic settings, use potassium binders to maintain RAASi therapy rather than discontinuing these mortality-reducing medications 2, 1